These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34293380)

  • 1. Polysubstance use trends and variability among individuals with opioid use disorder in rural versus urban settings.
    Ellis MS; Kasper ZA; Cicero TJ
    Prev Med; 2021 Nov; 152(Pt 2):106729. PubMed ID: 34293380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polysubstance use in rural West Virginia: Associations between latent classes of drug use, overdose, and take-home naloxone.
    Schneider KE; O'Rourke A; White RH; Park JN; Musci RJ; Kilkenny ME; Sherman SG; Allen ST
    Int J Drug Policy; 2020 Feb; 76():102642. PubMed ID: 31918401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polysubstance Use: A Broader Understanding of Substance Use During the Opioid Crisis.
    Cicero TJ; Ellis MS; Kasper ZA
    Am J Public Health; 2020 Feb; 110(2):244-250. PubMed ID: 31855487
    [No Abstract]   [Full Text] [Related]  

  • 4. Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.
    Bachyrycz A; Shrestha S; Bleske BE; Tinker D; Bakhireva LN
    Subst Abus; 2017; 38(1):55-60. PubMed ID: 27164192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polysubstance use latent class membership in New Jersey: Association with prior overdoses, prior emergency department peer recovery engagement, and mental health diagnosis among participants in an opioid overdose recovery program.
    Lardier DT; Gilmore Powell K; Peterson NA; Borys S; Hallcom DK
    Subst Abus; 2022; 43(1):1011-1022. PubMed ID: 35435801
    [No Abstract]   [Full Text] [Related]  

  • 6. A dynamic model of the opioid drug epidemic with implications for policy.
    Homer J; Wakeland W
    Am J Drug Alcohol Abuse; 2021 Jan; 47(1):5-15. PubMed ID: 32515234
    [No Abstract]   [Full Text] [Related]  

  • 7. Signals of increasing co-use of stimulants and opioids from online drug forum data.
    Sarker A; Al-Garadi MA; Ge Y; Nataraj N; Jones CM; Sumner SA
    Harm Reduct J; 2022 May; 19(1):51. PubMed ID: 35614501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with heroin use among those reporting -prescription opioid misuse: Results from a nationally -representative sample.
    Thomas AT; Fields KG; Kaye AD; Urman RD
    J Opioid Manag; 2022; 18(3):243-255. PubMed ID: 35666481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sociodemographic factors and social determinants associated with toxicology confirmed polysubstance opioid-related deaths.
    Barocas JA; Wang J; Marshall BDL; LaRochelle MR; Bettano A; Bernson D; Beckwith CG; Linas BP; Walley AY
    Drug Alcohol Depend; 2019 Jul; 200():59-63. PubMed ID: 31100636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vital Signs: Pharmacy-Based Naloxone Dispensing - United States, 2012-2018.
    Guy GP; Haegerich TM; Evans ME; Losby JL; Young R; Jones CM
    MMWR Morb Mortal Wkly Rep; 2019 Aug; 68(31):679-686. PubMed ID: 31393863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motivation and context of concurrent stimulant and opioid use among persons who use drugs in the rural United States: a multi-site qualitative inquiry.
    Fredericksen RJ; Baker R; Sibley A; Estadt AT; Colston D; Mixson LS; Walters S; Bresett J; Levander XA; Leichtling G; Davy-Mendez T; Powell M; Stopka TJ; Pho M; Feinberg J; Ezell J; Zule W; Seal D; Cooper HLF; Whitney BM; Delaney JAC; Crane HM; Tsui JI
    Harm Reduct J; 2024 Apr; 21(1):74. PubMed ID: 38561753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid use disorder treatment disruptions during the early COVID-19 pandemic and other emergent disasters: a scoping review addressing dual public health emergencies.
    Henderson R; McInnes A; Mackey L; Bruised Head M; Crowshoe L; Hann J; Hayward J; Holroyd BR; Lang E; Larson B; Leonard AJ; Persaud S; Raghavji K; Sarin C; Virani H; Wadsworth IW; Whitman S; McLane P
    BMC Public Health; 2021 Jul; 21(1):1471. PubMed ID: 34320954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polysubstance Use Patterns among Justice-Involved Individuals Who Use Opioids.
    Bunting AM; Oser C; Staton M; Knudsen H
    Subst Use Misuse; 2020; 55(13):2165-2174. PubMed ID: 32686551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rural communities face more than an opioid crisis: Reimagining funding assistance to address polysubstance use, associated health problems, and limited rural service capacity.
    Carpenedo Mun C; Schuler H; Baker R; Byrne F; Bresani E; Meyers K
    J Rural Health; 2023 Sep; 39(4):795-803. PubMed ID: 36775905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polysubstance Use Among Pregnant Women With Opioid Use Disorder in the United States, 2007-2016.
    Jarlenski MP; Paul NC; Krans EE
    Obstet Gynecol; 2020 Sep; 136(3):556-564. PubMed ID: 32769641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of co-occurring substance use in individuals with opioid use disorder.
    Mahoney JJ; Winstanley EL; Lander LR; Berry JH; Marshalek PJ; Haut MW; Marton JL; Kimble WD; Armistead M; Wen S; Cai Y; Hodder SL
    Addict Behav; 2021 Mar; 114():106752. PubMed ID: 33348147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
    Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR
    Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The changing landscape of naloxone availability in the United States, 2011 - 2017.
    Freeman PR; Hankosky ER; Lofwall MR; Talbert JC
    Drug Alcohol Depend; 2018 Oct; 191():361-364. PubMed ID: 30195192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid Overdose Experience, Risk Behaviors, and Knowledge in Drug Users from a Rural versus an Urban Setting.
    Dunn KE; Barrett FS; Yepez-Laubach C; Meyer AC; Hruska BJ; Petrush K; Berman S; Sigmon SC; Fingerhood M; Bigelow GE
    J Subst Abuse Treat; 2016 Dec; 71():1-7. PubMed ID: 27672239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in transmucosal buprenorphine utilization for opioid use disorder treatment during the COVID-19 pandemic in Kentucky.
    Lei F; Lofwall MR; Freeman PR; Slade E; Vickers-Smith R; Slavova S
    J Rural Health; 2023 Jan; 39(1):186-196. PubMed ID: 35610181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.